大肠癌、胃癌患者血清免疫抑制酸性蛋白检测的临床意义  

The clinical significance of the evaluation of serum immunosuppressive acidic protein in patients with colonuic carcinoma or with gastric carcinoma

作　　者：张海山[1] 房学东[1] 曹宏[1] 张岩[1] 金成山 田俊涛 

机构地区：[1]吉林大学中日联谊医院基本外科,吉林长春130031 [2]乾安县医院 [3]大安市医院

出　　处：《中国实验诊断学》2002年第2期96-97,共2页Chinese Journal of Laboratory Diagnosis

摘　　要：目的　按讨大肠癌、胃癌患者血清免疫抑制酸性蛋白（ＩＡＰ）检则的临床意义。方法　采用试剂盒提供的方法测定大肠癌患者３２例、胃癌患者２４例和正常对照３０例血清（ＩＡＰ）含量。结果　大肠癌患者血清ＩＡＰ为（６９０±１０８）×１０３μｇ／Ｌ，胃癌患者血清ＩＡＰ为（６４２±１１２）×１０３μｇ／Ｌ，与对照组血清ＩＡＰ值（３２１±１２８）×１０３μｇ／Ｌ比有显著性差异（Ｐ＜Ｏ．０１）；大肠癌组低期与高期、胃癌组低期与高期之间ＩＡＰ含量亦存在显著性差异（Ｐ＜０．０５）。大肠癌、胃癌患者血清ＩＡＰ较对照组明显升高，且随病情进展ＩＡＰ升高更加明显。结论ＩＡＰ可作为评估肿瘤患者免疫功能和预后的临床指标。Objective To evaluate the clinical significance of determination of serum immunosuppressive acidic protein (IAP)in patients with colonic or gastric carcinoma. Methods Serum IAP was determined in 32 patients with colonic carcinoma、.24 patients with gastric carcinoma and 30 controls. Results The value of IAP in patients with colonic carcinoma and in patients with gastric carcinoma was(690±108) × 103mμg/L and(642 ± 112) × 1μg/L respectively, the value of IAP was(321 ± 128) × 1μg/L in control group. There was significant difference between the study group and the control group( P < 0.01) and IAP increased with carcinoma advancement. Conclusions IAP is a potential indicator of patients immune system function and of prognosis of cancer patients.

关 键 词：大肠癌 胃癌 血清免疫抑制酸性蛋白 检测 临床意义 

分 类 号：R730.4[医药卫生—肿瘤]